The 71 linked references in paper N. Tsareva A., Н. Царева А. (2017) “Идиопатическая легочная артериальная гипертензия: современный подход к диагностике и лекарственной терапии // Idiopathic pulmonary arterial hypertension: current approach to diagnosis and pharmacological treatment” / spz:neicon:pulmonology:y:2017:i:2:p:216-231

  1. GaliéN., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J.2009; 34 (6): 1219–1263. DOI: 10.1183/ 09031936. 00139009.
  2. Vachiery J.-L., Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension.Eur. Respir. Rev. 2012; 21 (126): 313–320. DOI: 10.1183/09059180. 00005412.
  3. Chemla D., Castelain V., HervéP. et al. Haemodynamic evaluation of pulmonary hypertension.Eur. Respir. J.2002; 20 (5): 1314–1331. DOI: 10.1183/09031936.02.00068002.
  4. Benza R.L., Miller D.P., Gomberg-Maitland M. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122 (2): 164–172. DOI: 10.1161/CIRCULATIONAHA.109.898122.
  5. Badesch B.D., Champion H.C., Gomez-Sanchez M.A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.2009; 54 (30): S55–S56. DOI: 10.1016/ j.jacc.2009.04.011.
  6. Berger R.M., Beghetti M., Humpl T. et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012; 379 (9815): 537–546. DOI: 10.1016/S0140-6736(11) 61621-8.
  7. Trulock E., Edwards L., Taylor D. et al. Registry of the International Society for Heart and Lung Transplantation twenty fourth official adult lung and heart lung transplantation report 2007. J. Heart Lung Transplant.2007; 26 (8): 782–795. DOI: 10.1016/j.healun.2007.06.003.
  8. Stehlik J., Edwards L.B., Kucheryavaya A.Y. et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report–2010.J. Heart Lung Transplant.2010; 29 (10): 1089– 1103. DOI: 10.1016/j.healun.2010.08.007.
  9. Sitbon O., Morrell N.W. Pathways in pulmonary arterial hypertension: the future is here. Eur. Respir. Rev. 2012; 21 (126): 321–327. DOI: 10.1183/09059180.00004812.
  10. Solomon J.J., Olson A.L., Fischer A. et al. Scleroderma lung disease.Eur. Respir. Rev.2013; 22 (127): 6–19. DOI: 10.1183/ 09059180.00005512.
  11. Guazzi M., GaliéN. Pulmonary hypertension in left heart disease. Eur. Respir. Rev. 2012; 21 (126): 338–346. DOI: 10.1183/ 09059180.00004612.
  12. Diller G.P., Dimopoulos K., Okonko D. et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005; 112 (8): 828–835. DOI: 10.1161/CIRCULATIONAHA.104.529800.
  13. Peacock A.J., Murphy N.F., McMurray J.J.V. et al. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J.2007; 30 (1): 104–109. DOI: 10.1183/09031936. 0009 2306.
  14. GaliéN., Palazzini M., Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur. Heart J. 2010; 31 (1): 2080–2086. DOI: 10.1093/eurheartj/ehq152.
  15. Michelakis E.D. The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail. Rev. 2003; 8 (1): 5–21. DOI: 10.1023/A:1022150819223.
  16. Rubin L.J., Simonneau G., Badesch D. et al. The study of risk in pulmonary arterial hypertension.Eur. Respir. Rev. 2012; 21 (125): 234–238. DOI: 10.1183/09059180. 00003712.
  17. Humbert M., Souza R., Galie N. et al. Pulmonary arterial hypertension: bridging the present to the future.Eur. Respir. Rev.2012; 21 (126): 267–270. DOI: 10.1183/09059180. 00005312.
  18. 3; 62 (25, Suppl.): D35–D41. DOI: 10.1016/j.jacc. 2013.10.029. 20. Humbert M., Sitbon O., Yaici A. et al. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension.Eur. Respir. J. 2010; 36 (3): 549–555. DOI: 10.1183/ 09031936.00057010.
  19. GaliéN., Hoeper M., Torbicki A. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2009; 30 (20): 2493– 2537. DOI: 10.1093/eurheartj/ehr046.
  20. Nickel N., Golpon H., Greer M. et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.Eur. Respir. J.2012; 39 (3): 589–596. DOI: 10.1183/09031936.00092311.
  21. Soubrier F., Chung W.K., Machado R. et al. Genetics and genomics of pulmonary arterial hypertension.J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D13–D21. DOI: 10.1016/j.jacc. 2013.10.035.
  22. Eyries M., Montani D., Girerd B. et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension.Nat. Genet. 2014; 46 (1): 65–69. DOI: 10.1038/ng.2844.
  23. D’Alto M., Mahadevan V.S. Pulmonary arterial hypertension associated with congenital heart disease. Eur. Respir. Rev. 2012; 21(126): 328–337. DOI: 10.1183/09059180. 00004712.
  24. Huang J.B., Liang J., Zhou L.Y. Eisenmenger Syndrome: Not Always Inoperable. Respir. Care.2012; 57 (9): 1488–1495. DOI: 10.4187/respcare.01418.
  25. Rubin L.J., Badesch D.B. Evaluation and management of the patient with pulmonary arterial hypertension. Ann. Intern. Med. 2005; 143 (4): 282–292. DOI: 10.7326/0003-4819-143-4200508160-00009.
  26. GaliéN., Rubin L.J. Introduction: new insights into a challenging disease: A review of the third world symposium on pulmonary arterial hypertension. Am. Coll. Cardiol. J. 2004; 43 (12): S1. DOI: 10.1016/j.jacc.2004.03.003.
  27. GaliéN., Torbicki A., Barst R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart. J. 2004; 25 (24): 2243–2278. DOI: 10.1016/ j.ehj.2004. 09.014.
  28. Hambly N., Alawfi F., Mehta S. Pulmonary hypertension: diagnostic approach and optimal management. CMAJ. 2016; 188 (11): 804–812. DOI: 10.1503/cmaj.151075.
  29. McLaughlin V.V., Archer S.L., Badesch D.B. et al. ACCF/ AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009; 119 (16): 2250–2294. DOI: 10.1161/CIRCULATIONAHA. 109.192230.
  30. Lowe B.S., Therrien J., Ionescu-Ittu R. et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes.J. Am. Coll. Cardiol. 2011; 58 (5): 538–546. DOI: 10.1016/j.jacc.2011.03.033.
  31. Humbert M., Sitbon O., Chaouat A. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation.2010; 122 (2): 156–163. DOI: 10.1161/CIRCULATIONAHA.109.911818.
  32. Humbert M., Sitbon O., Yaici A. et al. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension. Eur. Respir. J.2010; 36 (3): 549–555. DOI: 10.1183/ 09031936.00057010.
  33. Stenmark K.R., Davie N., Frid M. et al. Role of the adventitia in pulmonary vascular remodeling. Physiology(Bethesda). 2006; 21 (2): 134–145. DOI: 10.1152/physiol. 00053.2005.
  34. GaliéN., Manes A., Branzi A. New insights on pulmonary arterial hypertension. Rev. Esp. Cardiol.2004; 57 (7): 603– 607. DOI: 10.1016/S1885-5857(06)60282-X.
  35. Duong-Quy S. Physiopathology of pulmonary hypertension: from bio-molecular mechanism to target treatment. J. Vasc. Med. Surg. 2016; 22 (4): 294–299. DOI: 10.4172/2329-6925. 1000294.
  36. Duplain H., Burcelin R., Sartori C. et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001; 104 (3): 342–345. DOI: 10.1161/01.CIR.104.3.342.
  37. Barst R.J., McGoon M., Torbicki A. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.2004; 43 (12, Suppl.): S40–S47. DOI: 10.1016/ j.jacc.2004.02.032.
  38. McLaughlin V.V., McGoon M.D. Pulmonary arterial hypertension. Circulation.2006; 114 (13): 1417–1431. DOI: 10.1161/ CIRCULATIONAHA.104.503540.
  39. Trip P., Nossent E.J., de Man F.S. et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur. Respir. J. 2013; 42 (6): 1575–1585. DOI: 10.1183/ 09031936.00184412.
  40. Sun X.G., Hansen J.E., Oudiz R.J., Wasserman K. Pulmonary function in primary pulmonary hypertension. J. Am. Coll. Cardiol.2003; 41 (6): 1028–1035. DOI: 10.1016/S0735-1097 (02)02964-9.
  41. Rudski L.G., Lai W.W., Afilalo J. et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J. Am. Soc. Echocardiogr. 2010; 23 (7): 685–713. DOI: 10.1016/j.echo. 2010. 05.010.
  42. Lang R.M., Badano L.P., Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging.2015; 28 (1): 1–39. DOI: 10.1016/j.echo.2014. 10.003.
  43. Lang I., Madani M. Update on Chronic Thromboembolic Pulmonary Hypertension. Circulation. 2014; 130 (6): 508– 518. DOI: 10.1161/CIRCULATIONAHA.114.009309.
  44. Sitbon O., Badesch D., Channick R. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003; 124 (1): 247–254. DOI: 10.1378/chest.124.1_suppl. 247S.
  45. Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet. 2001; 358 (9288): 1119–1123. DOI: 10.1016/ S0140-6736(01)06250-X.
  46. Barst R.J., Maislin G., Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999; 99 (9): 1197–1208. DOI: 10.1161/01.CIR.99.9.1197.
  47. Provencher S., Sitbon O., Humbert M. et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.Eur. Heart J. 2006; 27 (5): 589–595. DOI: 10.1093/eurheartj/ehi728.
  48. Rubin L., Badesch M., Barst R. et al. Randomized trial of endothelin antagonist therapy. N. Engl. J. Med. 2002; 346 (12): 896–903. DOI: 10.1056/NEJMoa012212.
  49. GaliéN., Olschewski H., Oudiz R.J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117 (23): 3010–3019. DOI: 10.1161/CIRCULATIONAHA.107. 742510.
  50. Oudiz R.J., GaliéN., Olschewski H. et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.2009; 52 (21): 1971–1981. DOI: 10.1016/j.jacc.2009.07.033.
  51. Badesch D.B., Feldman J., Keogh A. et al. ARIES3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.Cardiovasc. Ther.2012; 30 (2): 93–99. DOI: 10.1111/j.1755-5922.2011.00279.x.
  52. Pulido T., Adzerikho I., Channick R.N. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med.2013; 369 (9): 809–818. DOI: 10.1056/NEJ Moa1213917.
  53. GaliéN., Manes A. New treatment strategies for pulmonary arterial hypertension: hopes or hypes? J. Am. Coll. Cardiol. 2013; 62 (12): 1101–1102. DOI: 10.1016/j.jacc.2013. 06.032.
  54. Sitbon O., Humbert M., Nunes H. et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 2002; 40 (4): 780–788. DOI: 10.1016/S0735-1097(02) 02012-0.
  55. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106 (12): 1477–1482. DOI: 10.1161/01.CIR. 0000029100.82385.58.
  56. Simonneau G., Barst R.J., GaliéN. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med.2002; 165 (6): 800–804. DOI: 10.1164/ajrccm.165. 6.2106079.
  57. Hiremath J., Thanikachalam S., Parikh K. et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J. Heart Lung Transplant. 2010; 29 (2): 137–149. DOI: 10.1016/j.healun.2009.09.005.
  58. Tapson V.F., Gomberg-Maitland M., McLaughlin V.V. et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006; 129 (3): 683–688. DOI: 10.1378/chest. 129.3.683.
  59. Barst R.J., McGoon M., McLaughlin V.V. et al. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2003; 41 (12): 2119–2125. DOI: 10.1016/S0735-1097(03) 00463-7.
  60. Olschewski H., Simommeau G., GaliéN. et al. Inhaled iloprost in severe pulmonary hypertension.N. Engl. Med. 2002; 347 (5): 322–329. DOI: 10.1056/NEJMoa020204.
  61. McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.2006; 174 (11): 1257–1263. DOI: 10.1164/rccm.200603-358OC.
  62. Ghofrani H.A., Rose F., Schermuly R.T. et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol.2003; 42 (1): 158–164. DOI: 10.1016/S0735-1097(03) 00555-2.
  63. Evgenov O.V., Pacher P., Schmidt P.M. et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov.2006; 5 (9): 755–768. DOI: 10.1038/nrd2038.
  64. Schermuly R.T., Stasch J.P., Pullamsetti S.S. et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur. Respir. J.2008; 32 (4): 881–891. DOI: 10.1183/09031936.00114407.
  65. Stasch J.P., Evgenov O.V. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb. Exp. Pharmacol. 2013; 218 (1): 279–313. DOI: 10.1007/978-3-642-38664-0_12.
  66. Ghofrani H.A., Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur. Respir. Rev.2009; 18 (111): 35–41. DOI: 10.1183/ 09059180.00011112.
  67. Stasch J.P., Hobbs A. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb. Exp. Pharmacol. 2009; (191): 277–308. DOI: 10.1007/978-3-540-68964-5_13.
  68. Ghofrani H.A., GaliéN., Grimminger F. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2013; 369 (4): 330–340. DOI: 10.1056/NEJMoa 1209655.
  69. Ghofrani H.A., D'Armini A., Grimminger F. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med.2013; 369 (4): 319–329. DOI: 10.1056/ NEJMoa1209657.
  70. Царева Н.А., Авдеев С.Н., Неклюдова Г.В. Последовательная комбинированная терапия у больной идиопатической легочной артериальной гипертензией. Кардиология.2016; 56 (3): 97–100. DOI: 10.18565/cardio.2016.3.97-100.
  71. McLaughlin V.V., Channik R., Chin K.M. et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. J. Am. Coll. Cardiol.2015; 65 (10): 1538–1588. DOI: 10.1016/S0735-1097(15)61538-8. Поступила 21.02.17